Symptom distress, stress, and quality of life in the first year of gynaecological cancers: A longitudinal study of women in Taiwan

To assess changes in symptom distress, stress, and quality of life (QOL) during chemotherapy and three months after its completion, as well as to identify predictors of QOL in the first year after a gynaecological cancer diagnosis in Taiwanese women. A prospective, longitudinal study was conducted from August 2017 to July 2019, recruiting 97 patients with gynaecological cancer at a large teaching hospital in central Taiwan. Data were obtained at four time points: after the first, third, and sixth chemotherapy cycles, and three months after treatment completion. Participants completed Chinese versions of three validated questionnaires: World Health Organization QOL Brief version, Symptom Distress Scale, and Perceived Stress Scale. Linear regression analyses with generalised estimating equations were used to examine the associations between symptom distress, stress, and QOL over time. Fatigue, feeling desperate about the future, and peripheral limb numbness were the three major problems during the first year of gynaecological cancers. Feeling desperate about the future and stress were significant predictors of QOL in all domains. Noticeably, the level of stress increased over time, especially at three months after treatment completion. Participants reported fair QOL levels that gradually improved over time. Stress and chemotherapy-induced symptom distress were factors that most interfered with QOL in women with gynaecologic cancers. Therefore, integrating psychological care and symptom support is an essential part of meeting patients’ QOL needs. •Fatigue, desperation, and peripheral limb numbness are the first-year problems.•Major predictors of quality of life are stress and desperation during chemotherapy period and three months later.•Stress plays an important role in relieving chemotherapy-induced distress.•Nurses should focus on stress screening to maintain patients' quality of life.